BRIEF-Alnylam Announces Expansion Of "Orphan Drug" Status For Patisiran
December 11, 2017 at 07:13 AM EST
* ALNYLAM ANNOUNCES EXPANSION OF U.S. ORPHAN DRUG DESIGNATION FOR PATISIRAN TO TREATMENT OF TRANSTHYRETIN-MEDIATED AMYLOIDOSIS Source text for Eikon: Further company coverage:
